financetom
Business
financetom
/
Business
/
Intuit Insider Sold Shares Worth $4,999,470, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Intuit Insider Sold Shares Worth $4,999,470, According to a Recent SEC Filing
Mar 26, 2025 12:39 AM

03:14 AM EDT, 03/26/2025 (MT Newswires) -- Laura A Fennell, Executive Vice President, People and Places, on March 24, 2025, sold 8,163 shares in Intuit (INTU) for $4,999,470. Following the Form 4 filing with the SEC, Fennell has control over a total of 33,577 common shares of the company, with 21,882 shares held directly and 11,695 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/896878/000162828025014823/xslF345X05/wk-form4_1742950163.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Neurocrine Gets FDA Approval for Ingrezza Sprinkle Capsules; Shares Rise After-Hours
Neurocrine Gets FDA Approval for Ingrezza Sprinkle Capsules; Shares Rise After-Hours
Apr 30, 2024
05:45 PM EDT, 04/30/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said late Tuesday the US Food and Drug Administration approved the Ingrezza Sprinkle capsules to treat adults with tardive dyskinesia and chorea related to Huntington's disease. Tardive dyskinesia is a movement disorder, while Huntington's disease is a neurodegenerative disorder. The company said the capsules offer an alternative option...
Neurocrine Biosciences' Huntington's disease drug gets FDA approval
Neurocrine Biosciences' Huntington's disease drug gets FDA approval
Apr 30, 2024
April 30 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' ( NBIX ) INGREZZA drug to treat movement disorders associated with Huntington's disease, the company said on Tuesday. Huntington's disease is an inherited condition that causes the progressive breakdown of nerve cells in the brain, resulting in a gradual decline in...
ICON Prices $2 Billion Debt Offering
ICON Prices $2 Billion Debt Offering
Apr 30, 2024
05:44 PM EDT, 04/30/2024 (MT Newswires) -- ICON (ICLR) said late Tuesday it priced a $2 billion bond offering. The offering comprises $750 million of 5.809% senior secured notes due 2027, $750 million of 5.849% senior secured notes due 2029 and $500 million of 6% senior secured notes due 2034. The company expects the offering to close May 8 with...
IBM wins reversal of $1.6 billion judgment to BMC over software contract
IBM wins reversal of $1.6 billion judgment to BMC over software contract
Apr 30, 2024
April 30 (Reuters) - A federal appeals court on Tuesday overturned a judgment requiring IBM ( IBM ) to pay rival BMC Software $1.6 billion, after a judge found IBM ( IBM ) improperly replaced BMC's mainframe software at AT&T ( T ) with its own. The 5th U.S. Circuit Court of Appeals in New Orleans said a lower court...
Copyright 2023-2026 - www.financetom.com All Rights Reserved